GLTO vs. RNXT, KZIA, ONTX, NHWK, APRE, TNXP, CNTX, NNVC, BFRG, and CALC
Should you be buying Galecto stock or one of its competitors? The main competitors of Galecto include RenovoRx (RNXT), Kazia Therapeutics (KZIA), Onconova Therapeutics (ONTX), NightHawk Biosciences (NHWK), Aprea Therapeutics (APRE), Tonix Pharmaceuticals (TNXP), Context Therapeutics (CNTX), NanoViricides (NNVC), Bullfrog AI (BFRG), and CalciMedica (CALC). These companies are all part of the "pharmaceutical preparations" industry.
Galecto (NASDAQ:GLTO) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.
Galecto has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.
Galecto currently has a consensus target price of $7.60, suggesting a potential upside of 988.83%. RenovoRx has a consensus target price of $13.00, suggesting a potential upside of 900.00%. Given Galecto's higher probable upside, analysts clearly believe Galecto is more favorable than RenovoRx.
29.4% of Galecto shares are held by institutional investors. Comparatively, 2.3% of RenovoRx shares are held by institutional investors. 12.1% of Galecto shares are held by insiders. Comparatively, 9.0% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Galecto had 2 more articles in the media than RenovoRx. MarketBeat recorded 4 mentions for Galecto and 2 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.44 beat Galecto's score of 0.64 indicating that RenovoRx is being referred to more favorably in the news media.
Galecto's return on equity of -90.21% beat RenovoRx's return on equity.
RenovoRx is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks.
Galecto received 25 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 60.00% of users gave Galecto an outperform vote while only 35.71% of users gave RenovoRx an outperform vote.
Summary
Galecto beats RenovoRx on 11 of the 15 factors compared between the two stocks.
Get Galecto News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools